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esponsibility of InstAbstract Acute lung injury (ALI) or acute respiratory distress syndrome (ARDS) is a severe, life-
threatening medical condition characterized by widespread inﬂammation in the lungs, and is a
signiﬁcant source of morbidity and mortality in the patient population. New therapies for the
treatment of ALI are desperately needed. In the present study, we examined the effect of
andrographolide sulfonate, a water-soluble form of andrographolide (trade name: Xi-Yan-Ping
Injection), on lipopolysaccharide (LPS)-induced ALI and inﬂammation. Andrographolide sulfonate
was administered by intraperitoneal injection to mice with LPS-induced ALI. LPS-induced airway
inﬂammatory cell recruitment and lung histological alterations were signiﬁcantly ameliorated by
andrographolide sulfonate. Protein levels of pro-inﬂammatory cytokines in bronchoalveolar lavage
ﬂuid (BALF) and serum were reduced by andrographolide sulfonate administration. mRNA levels of
pro-inﬂammatory cytokines in lung tissue were also suppressed. Moreover, andrographolide sulfonate
markedly suppressed the activation of mitogen-activated protein kinase (MAPK) as well as p652
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Shuang Peng et al.206subunit of nuclear factor-κB (NF-κB). In summary, these results suggest that andrographolide
sulfonate ameliorated LPS-induced ALI in mice by inhibiting NF-κB and MAPK-mediated
inﬂammatory responses. Our study shows that water-soluble andrographolide sulfonate may represent
a new therapeutic approach for treating inﬂammatory lung disorders.
& 2016 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical
Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Inﬂammatory lung diseases, including acute lung injury (ALI),
acute respiratory distress syndrome, and pneumonia, are life-
threatening diseases which cause high morbidity and mortality
world-wide1,2. Many factors such as sepsis, shock, trauma and
burns can lead to ALI. It is well established that lipopolysaccha-
ride (LPS)-induced inﬂammation in the lung is mediated by several
pro-inﬂammatory mediators, and is one of the main reasons for
ALI3–5. After stimulation by LPS, TLR4 recruits TIRAP, MyD88
and IRAK kinases, forming a multi-molecular complex which
triggers a signaling cascade leading to activation of nuclear factor-κB
(NF-κB) and mitogen-activated protein kinase (MAPK) and
controls the production of inﬂammatory cytokines, such as tumor
necrosis factor-α (TNF-α) and interleukin-6 (IL-6)6,7. Despite the
elucidation of the pathogenic factors of ALI through extensive
investigations, current treatments fail to reduce lung injury and
mortality8,9. Therefore, new and effective strategies are still
required for ALI patients.
Andrographolide sulfonate, a water-soluble form of androgra-
pholide made through a sulfonating reaction, is an andrographolide
sulfate mixture and has been made into an injection dosage form
for intramuscular injection and intravenous drip. It has been used
in China for many years, mainly for therapy of bronchitis,
paristhmitis and bacillary dysentery. The effect of andrographolide
sulfonate on LPS-induced sepsis and trinitrobenzenesulfonic acid
(TNBS)- or dextran sulfate sodium (DSS)-induced colitis has been
demonstrated10–12. In the present study, we examined the anti-ALI
effect of andrographolide sulfonate and showed that andrographo-
lide sulfonate signiﬁcantly inhibited MAPK and NF-κB pathways
and reduced the susceptibility to LPS-induced ALI in mice.2. Materials and methods
2.1. Animals
Female C57BL/6 mice, aged 6–8 weeks, were purchased from
Model Animal Research Center of Nanjing University (Nanjing,
China). Mice were maintained in an animal facility under standard
laboratory conditions for 1 week prior to experiments, and provided
water and standard chow. Animal welfare and experimental proce-
dures were carried out in accordance with the Guide for the Care and
Use of Laboratory Animals. All efforts were made to reduce the
number of animals used and to minimize animals’ suffering.
2.2. Agents
Andrographolide sulfonate (trade name: Xi-Yan-Ping Injection)
was provided by Jiangxi Qingfeng Pharmaceutical Co., Ltd.(Ganzhou, China). LPS (from Escherichia coli (0111:B4)) was
purchased from Sigma-Aldrich (St. Louis, MO, USA). ELISA kits
for TNF-α, IL-6 and IL-1β were purchased from Dakewei
(Beijing, China). Anti-phosphorylation of c-Jun N-terminal kinase
(JNK) (Thr183/Tyr185), anti-phosphorylation of ERK1/2 (Thr202/
Tyr204), anti-phosphorylation of p38 (Thr180/Tyr182), anti-
phosphorylation of p65 were purchased from Cell Signaling
Technology (Beverly, MA, USA). Anti-mouse CD3-FITC,
CD11b-PE and CD11c-APC antibodies were bought from
eBioscience. (San Diego, CA, USA) GTVisin™ anti-mouse/anti-
rabbit immunohistochemical analysis KIT was purchased from
Gene Company (Shanghai, China). All other chemicals were
obtained from Sigma-Aldrich (St. Louis, MO, USA).
2.3. Induction of acute lung injury by LPS inhalation
ALI in mice were induced by inhaling atomized LPS (500 μg/mL)
for 30 min at 2 h intervals over a 4 h period. Mice were randomly
divided into 5 groups (n¼8 per group): control group inhaled
atomized PBS, model group inhaled atomized LPS. Andrographo-
lide sulfonate (2.5, 5 and 10 mg/kg) dissolved in saline was given
to mice once per day (i.p.) for 3 days before inhalation of LPS.
Mice were killed 1 h after administration of LPS. Bronchoalveolar
ﬂuid (BALF), blood plasma and tissue samples were collected. For
BALF collection, mice were perfused with ice cold PBS. The
lungs were lavaged for three times with 1 mL of saline, and the
resultant BALF was centrifuged to separate the cellular compo-
nents from the supernatants. Total BALF cell number was
determined and the BALF cells were stained with anti-mouse
CD3-FITC, CD11b-PE and CD11c-APC antibodies and the
composition was evaluated by ﬂuorescence-activated cell sorting
(FASC) analysis.
2.4. Histological analysis
To examine histological changes, lungs from animals in each
group were taken and ﬁxed in 10% formalin, embedded in
parafﬁn, and then sectioned to reveal the maximum longitudinal
view of the main intrapulmonary bronchus of the left lung lobe. A
histopathologic study was conducted using hematoxylin & eosin
(H&E)-stained lung sections. Alveolar congestion, hemorrhage,
inﬁltration or aggregation of inﬂammatory cells in airspaces or
vessel walls, and the thickness of the alveolar walls were assessed.
2.5. Cytokine analysis by ELISA
Serum was collected from blood of mice by centrifugation at
3500 × g for 15 min. Serum cytokine levels were measured by
speciﬁc ELISA kits (Dakawe, Beijing, China) as instructed.
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Real-time PCR was performed as follows: RNA samples from
lung tissues of mice in each group were extracted and reversed to
cDNA and subjected to quantitative PCR, which was performed
with the BioRad CFX96 Touch™ Real-Time PCR Detection
System (BioRad，USA) using iQ™ SYBRs Green Supermix,
and threshold cycle numbers were obtained using BioRad CFX
Manager software. The program for ampliﬁcation was 1 cycle of
95 1C for 2 min followed by 40 cycles of 95 1C for 10 s, 60 1C for
30 s, and 95 1C for 10 s. The primer sequences used in this study
were as follows: Tnf-α forward 50-CGAGTGACAAGCCTG-
TAGCCC-30; Tnf-α reverse 50-GTCTTTGAGATCCATGCCGT
TG-30; Il-1β forward 50-CTTCAGGCAGGCAGTATCACTC-30;
Il-1β reverse 50-TGCAGTTGTCTAATGGGAACGT-30; Il-4 for-
ward 50-GTCTGCTGTGGCATATTCTG-30; Il-4 reverse 50-GGC
ATTTCTCATTCAGATTC-30; Il-5 forward 50-GGCTACACA-
GAGAAACCCTGT-30; Il-5 reverse 50-CATGCATACACAGG
TAGTTCA-30; Il-6 forward 50-ACAACCACGGCCTTCCCTAC-
30; Il-6 reverse 50-TCTCATTTCCACGATTTCCCAG-30; Il-17a
forward 50-TCGAGAAGATGCTGGTGGGT-30; Il-17a reverse 50-
CTCTGTTTAGGCTGCCTGGC-30; β-actin forward 50-TGCTG
TCCCTGTATGCCTCT-30; β-actin reverse 50-TTTGATGTCAC
GCACGATTT-30.2.7. Western blot
Protein from lung tissue was extracted in lysis buffer (30 mmol/L
Tris, pH 7.5, 150 mmol/L sodium chloride, 1 mmol/L phenyl-
methylsulfonyl ﬂuoride, 1 mmol/L sodium orthovanadate, 1%
Nonidet P-40, 10% glycerol, and phosphatase and protease
inhibitors). The protein content of the supernatant was determined
by BCA protein assay Kit (Pierce, Rochford, IL). The proteins
were then separated by SDS-PAGE and electrophoreticallyFigure 1 Andrographolide sulfonate treatment ameliorated LPS-induce
sulfonate by intraperitoneal injection (2.5, 5 and 10 mg/kg) for days 0–2. A
subjected to H&E staining. Values are shown as mean7SEM of 8 mic
andrographolide sulfonate.transferred onto polyvinylidene ﬂuoride membranes. The mem-
brane was blocked with 5% skimmed milk for 1 h at room
temperature. The blocked membrane was incubated with the
indicated primary antibodies overnight at 4 1C, and then incubated
with horseradish peroxidase (HRP)-coupled secondary antibody.
Detection was performed using a LumiGLO chemiluminescent
substrate system (KPL, Guildford, UK).
2.8. Immunohistochemical analysis
Immunohistochemical analysis was performed on parafﬁn-
embedded lung tissue sections (5 μm) as described previously10.
2.9. Statistical analysis
Data are expressed as mean7SEM. ANOVA with post hoc
comparisons was used to evaluate the differences between experi-
mental and control groups. P values less than 0.05 were considered
signiﬁcant.3. Results
3.1. Andrographolide sulfonate inhibited inﬁltration of inﬂammatory
cells and pathological changes of LPS-induced lung injury in mice
In order to verify whether andrographolide sulfonate can improve
lung inﬂammation, we used a mouse model of LPS-induced acute
lung injury to evaluate the therapeutic effect of andrographolide
sulfonate. Mice were challenged with LPS and lung tissue samples
were collected. The sections stained with H&E was shown in
Fig. 1. Lung tissues from the LPS group demonstrated signiﬁ-
cantly pathological alterations, including notable inﬂammatory
cells inﬁltration, interstitial and intra-alveolar edema and patchyd acute lung injury in mice. Mice were given by andrographolide
fter LPS inhalation on day 2, lung tissue was ﬁxed in 4% formalin and
e. *Po0.05, **Po0.01 vs. mice treated with LPS alone. Andro-S:
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alveoli. Against these changes, treatment with andrographo-
lide sulfonate markedly reduced the extent of tissue damage.
The histology score also showed that andrographolide sulfonate
dose-dependently alleviated lung tissue damage. Next, the inﬁltra-
tion of inﬂammatory cells in BALF was quantiﬁed. The number of
total inﬁltrated cells, T cells (CD3þ), macrophages (CD11bþ) and
neutrophils (Gr1þ), in BALF were examined by FACS. As shown
in Fig. 2, LPS stimulation-induced inﬁltration of inﬂammatory cell
was dose-dependently reduced with andrographolide sulfonate
treatment.
3.2. Andrographolide sulfonate inhibited levels of cytokines in
BALF and serum
After LPS inhaled-administration, the inﬁltration of inﬂammatory
cells signiﬁcantly increased and levels of inﬂammatory cytokines
in BALF and serum were all elevated; however, these effects were
attenuated by andrographolide sulfonate treatment. As shown in
Fig. 3, andrographolide sulfonate signiﬁcantly reduced the con-
centrations of TNF-α, IL-6 and IL-1β both in BALF and serum.
3.3. Andrographolide sulfonate inhibited mRNA expression of
inﬂammatory cytokines induced by LPS in the injured lung
Since andrographolide sulfonate signiﬁcantly inhibited the BALF
and serum levels of TNF-α and IL-1β, the mRNA levels of various
proinﬂammatory cytokines in the injured lung was measured. As
shown in Fig. 4, the mRNA levels of Il-4, Il-5, Il-1β, Tnf-α and
Il-6 were remarkably increased after LPS challenge while there
was no change of Il-17a level. Andrographolide sulfonateFigure 2 Andrographolide sulfonate treatment prevented LPS-induced re
was collected and the cells present in BALF were counted (A). Cells were
APC (D) and analyzed by FACS. Values are shown as the mean7SD of 8
andrographolide sulfonate.signiﬁcantly inhibited the elevated expression of cytokines in a
dose-dependent manner.3.4. Andrographolide sulfonate reduced LPS-induced activation
of MAPK and NF-κB signaling
After administration of LPS, MAPK and NF-κB were activated
leading to the transcription of various genes involved in inﬂam-
mation as shown in Fig. 4. LPS administration caused phosphory-
lation of p38, ERK, JNK, as well as p65 in the injured lung from
mice with ALI (Fig. 5B and C). Andrographolide sulfonate
treatment markedly reduced the phosphorylation of p38, JNK
and NF-κB as well as ERK to some extent. Immunohistochemical
staining revealed an increased level of p-p65 after LPS stimulation,
and andrographolide sulfonate administration markedly inhibited
the phosphorylation of p65 (Fig. 5A).4. Discussion
Clinical treatment of acute lung injury is based on both ventilatory
and nonventilatory strategies. Lung-protective strategies that
include mechanical ventilation therapies have an established
survival advantage13. Although numerous pharmacologic therapies
have been provided, all have failed to demonstrate beneﬁt in
multicenter clinical trials14,15.
Acute lung injury is a serious illness characterized by acute
inﬂammation and disruption of the lung endothelial and epithelial
barriers. Excess production of inﬂammatory cytokines and increased
permeability of the alveolar-capillary barrier occurred following
infection or trauma. When mice inhaled LPS, they exhibited thesecruitment of inﬂammatory cells in lung tissue. BALF from each group
stained with antibodies to CD3-FITC (B), CD11b-PE (C) and CD11c-
mice. nPo0.05, nnPo0.01 vs. mice treated with LPS group. Andro-S:
Figure 4 Andrographolide sulfonate suppressed mRNA levels of inﬂammatory cytokines in lung of mice with LPS-induced ALI. RNA of lung
tissue was extracted. The mRNA expression of Il-6, Tnf-α, Il-1β, Il-4, Il-5, Il-17a was examined by real-time PCR.Values were shown as the
mean7SEM of 6 mice. nPo0.05, nnPo0.01 vs. mice treated with LPS alone. Andro-S: andrographolide sulfonate.
Figure 3 Andrographolide sulfonate treatment suppressed LPS-induced cytokine secretion. Cytokine levels in BALF supernatant (A) and serum
(B) from each group were determined by ELISA. Values are shown as the mean7SD of 8 mice. nPo0.05, nnPo0.01 vs. mice treated with LPS
group. Andro-S: andrographolide sulfonate.
Andrographolide sulfonate ameliorates lung injury 209symptoms16,17. In the current study, our data revealed that andro-
grapholide sulfonate attenuated the LPS-induced lung histopathologic
changes, lung edema and inﬂammatory cytokine production andactivation of NF-κB and thus protected mice against LPS-induced
induced acute lung injury. These results indicated that andrographolide
sulfonate exerted potential protective effects against LPS-induced ALI.
Figure 5 Andrographolide sulfonate decreased activation of MAPK and NF-κB in the lungs of mice with LPS-induced ALI. (A) Parafﬁn-
embedded lung tissue sections from vehicle- and andrographolide sulfonate-treated groups were stained for p-p65. Original magniﬁcation, 100 ;
(B) lung tissue protein was extracted from the treated mice and protein levels of p-p38, p-ERK, p-JNK and p-p65 were examined by western blot.
Andro-S: andrographolide sulfonate.
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of Andrographis paniculata, which has been used in China for
many years. It has been reported that andrographolide possesses
antibacterial, anti-inﬂammatory and antiviral activities18,19. Andro-
grapholide sulfonate is a water-soluble mixture made from andro-
grapholide through a sulfonating reaction. The main constituents are
17-hydro-9-dehydroandrographolide-3,19-disodium sulfonate, 17-
hydro-9-dehydroandrographolide-3-sodium sulfonate, 17-hydro-9-
dehydroandrographolide-19-sodium sulfonate, and 17-hydro-9-
dehydroandrographolide10. Although we have not yet puriﬁed any
of these components, intraperitoneally injection of total androgra-
pholide sulfonate at the dose of 2.5, 5 and 10 mg/kg signiﬁcantly
reduced the inﬁltration of prominent inﬂammatory cells (including
alveolar macrophages, neutrophils and T cells) (Figs. 1 and 2),
inhibited the release of cytokines (such as TNF-α, IL-1β and IL-6)
in BALF and serum (Fig. 3) thus alleviating the lung damage.
It is known that inﬂammatory stimuli such as LPS led to the
activation of MAPK and the transcription factor NF-κB, which
mediates the expression of several pro-inﬂammatory cytokines,
including TNF-α, IL-1β, and IL-6, playing an important role in
many inﬂammatory disease processes20–22. The possibility that
andrographolide inhibits NF-κB activity has been investigated
in vitro in that it can bind to p5023. Our study showed that
andrographolide sulfonate treatment can inhibit phosphorylation of
both MAPK (p38, JNK and ERK) and NF-κB, suggesting that
andrographolide sulfonate may work on the upstream portion of
LPS-TLR4-induced signaling.
Above all, our data here showed that andrographolide sulfonate
can inhibit LPS-induced cytokine production with a possible mechan-
ism for negative regulation NF-κB and MAPK activation, and thus
attenuate acute lung injury in mice. The detailed mechanism needs
further exploration. These results provide evidence for the possible
clinical application of andrographolide sulfonate for ALI.
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